RxDoctor Payments Data

Faraj Kargoli, MD

Interventional Cardiology · Mesa, AZNPI 1295122638

Payments from drug & device makers

What this record shows

This record is dominated by grants: $88,000 of the $114,876 with a category attached, or 76.6%. Abbott accounts for 70.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $68,787 and has fallen 91.5% since, to $5,845 in 2025. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$114,876in general payments, 2019–2025

Across 285 payments — averaging $403.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$81K
  • Medtronic$19K
  • Edwards Lifesciences$8K
  • Angiodynamics, Inc.$2K
  • Abiomed$784
  • Boston Scientific$737
  • plus $3K from 19 others

What the payments were for

  • Grants$88,00077%
  • Travel & lodging$9,5928%
  • Food & beverage$17,05615%
  • Education$2290%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,876 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$27,132
Medicare patients
64
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate30$229

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →